Audrey Sternberg | Authors


Real-World Evidence Supports Efficacy of Palbociclib Plus Letrozole in HR+/HER2– Breast Cancer

April 09, 2021

An analysis of real-world outcomes in a cohort of patients treated in mostly community settings showed that palbociclib plus letrozole improved both progression-free and overall survival in women with hormone receptor–positive, HER2-negative metastatic breast cancer.

Umbralisib Activity, Safety in Indolent Lymphomas Demonstrated in Phase 2b Trial

April 06, 2021

Data that led to the approval of umbralisib in patients with indolent non-Hodgkin lymphoma— including follicular lymphoma and marginal zone lymphoma—indicates favorable activity of the therapy versus other available PI3K inhibitors.

Long-Term OS Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful Boost

April 05, 2021

With more than 5 years of follow-up, results from the SOLO2 trial of olaparib maintenance in relapsed, high-grade serous or endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer, were reported and showed superiority of the agent over placebo.